68.2 F
Fort Worth
Tuesday, September 22, 2020
- Advertisements -
Business Encore Vision begins clinical development trails for eye treatment

Encore Vision begins clinical development trails for eye treatment

Other News

Wall Street posts solid gains after surge in corporate deals

By ALEX VEIGA and DAMIAN J. TROISE AP Business Writers Wall Street kicked off the week with a broad...

Tarrant County ranks low in work-from-home study by NAR

North Texas ranks pretty high in the “Work from Home” category, according to a just-released study by the National Association of Realtors....

Commentary: Universities and COVID-19: Charting turbulent times

Ray Perryman As the COVID-19 pandemic emerged this spring, college campuses across the United States swiftly sent students...

Linear Labs introduces electric motor that will fit inside a pocket

Leading the new wave of electrification, a Fort Worth-based technology company has built an electric motor that can fit inside one's pocket,...
Robert Francis
Robert Francis
Robert is a Fort Worth native and longtime editor of the Fort Worth Business Press. He is a former president of the local Society of Professional Journalists and was a freelancer for a variety of newspapers, weeklies and magazines, including American Way, BrandWeek and InformatonWeek. A graduate of TCU, Robert has held a variety of writing and editing positions at publications such as the Grand Prairie Daily News and InfoWorld. He is also a musician and playwright.

Encore Vision Inc. said last week that the U.S. Food and Drug Administration has given Encore’s Investigational New Drug application an approval as safe, allowing the Fort Worth-based company to proceed with clinical development of a treatment for presbyopia.

Presbyopia is a visual condition that develops around age 40 that often leads to reading glasses. Encore says that since that approval it has enrolled the first subject into their Phase 1 and 2 trial, which it believes to be the first ever clinical evaluation of a new chemical entity intended to address an underlying process that causes presbyopia.

“The FDA clearance of our IND for EV06 and subsequent enrollment of the first patient into our study are two significant milestones for Encore Vision,” said Bill Burns, president and CEO of Encore Vision. “Our company was founded with the goal of developing treatments for presbyopia, which affects 9 out of 10 Americans over 40. EV06 ophthalmic solution addresses stiffening of the lens, thought to be a root cause of presbyopia. We are excited to advance the clinical development of EV06 and bring this novel therapeutic treatment one step closer to over a billion people affected by presbyopia worldwide.”

Encore’s product, EV06, is an investigational proprietary lipoic acid choline ester compound that is being developed to treat presbyopia by reversing age-related changes in the crystalline lens that result in diminished lens elasticity, according to the company. The Phase 1 and 2 prospective, will compare the safety and efficacy of EV06 to placebo in subjects 45 to 55 years of age with presbyopia. The 90-day study will aim to enroll 72 subjects and evaluate mean change in distance corrected near visual acuity (DCNVA) and best corrected distance visual acuity (BCDVA), along with additional secondary outcomes.

In 2014, the company completed a $1.7 million round of funding to help develop EV06.

- Advertisements -
- Advertisements -

Latest News

Powell and Mnuchin voice optimism but back more economic aid

By MARTIN CRUTSINGER AP Economics Writer WASHINGTON (AP) — Federal Reserve Chairman Jerome Powell and Treasury Secretary Steven Mnuchin...

Tarrant County reports 3 COVID deaths on Tuesday

Tarrant County Public Health reported three COVID-19 deaths on Tuesday, Sept. 22. The deceased include a woman from Fort Worth in her...

Fort Worth police partner with MHMR and The Morris Foundation on mental health

The Fort Worth Police Department, with funding from The Morris Foundation and support by My Health My Resources (MHMR), will assure that...

Wall Street steadies itself, halting 4-day losing streak

By STAN CHOE, DAMIAN J. TROISE and ALEX VEIGA AP Business Writers Stocks on Wall Street shrugged off an...

Powell: Many small companies can borrow without Main Street

By CHRISTOPHER RUGABER AP Economics WriterWASHINGTON (AP) — Federal Reserve Chair Jerome Powell says that many mid-size U.S. businesses are now able...